Clinical trials
Neovascular Age-Related Macular Degeneration (nAMD) clinical trials
Below are recruiting neovascular age-related macular degeneration (namd) clinical trials, each written for real people, not researchers. We’re tracking 31 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06492863RecruitingPhase 1/Phase 2
Gene therapy (FT-003) for wet AMD
This trial tests a new gene therapy, FT-003, for people with wet AMD. It aims to see if a single treatment can help stop vision loss and may reduce the need for frequent eye injections.
Tianjin, Tianjin,ChinaAges 50–80 - NCT07776522RecruitingPhase 2
Gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
Beijing, Beijing MunicipalityAges 50–85 - NCT07695207RecruitingPhase 3
Testing SMZ1 with ranibizumab for wet macular degeneration
This trial tests a new medicine called SMZ1 combined with ranibizumab (a standard treatment) for people with wet macular degeneration. It may help improve vision by targeting the cause of the disease more effectively.
Seoul, SeoulAges 50 years+ - NCT07660640Enrolling by invitation
Long-term follow-up for VOY-101 eye injection study
This study follows up with people who already received the VOY-101 injection for a type of age-related vision loss (non-neovascular age-related macular degeneration) in an earlier study. It checks how they are doing over a longer period of time.
Boston, MassachusettsAges 50 years+ - NCT06141460RecruitingPhase 1/Phase 2
Gene therapy trial for wet age-related macular degeneration
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
Tianjin, Tianjin MunicipalityAges 50 years+ - NCT07640997Recruiting
Real-world study of aflibercept for age-related macular degeneration
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
Beijing, Beijing MunicipalityAges 50 years+ - NCT07630649RecruitingPhase 2
Gene therapy for wet age-related macular degeneration in second eye
This study tests a one-time gene therapy injection (ixoberogene soroparvovec) in the second eye of people with wet age-related macular degeneration who have already responded well to anti-VEGF injections. The goal is to see if this gene therapy can help preserve or improve vision in that eye.
Phoenix, ArizonaAges 50 years+ - NCT07614776RecruitingPhase 3
New Eye Injection Treatment for Age-Related Macular Degeneration
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Fullerton, CaliforniaAges 50 years+ - NCT05672121RecruitingPhase 1/Phase 2
Gene therapy safety study for neovascular macular degeneration
This trial tests a new gene therapy drug (KH631) to see if it is safe and tolerated in people with neovascular age-related macular degeneration (nAMD). It may help your retina problems, but the early goal is mainly to learn about side effects and how the treatment behaves in the eye.
BeijingAges 50–85 - NCT06458595RecruitingPhase 1/Phase 2
Gene therapy for wet age-related macular degeneration (nAMD)
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
TianjinAges 50–85 - NCT07547228RecruitingPhase 1/Phase 2
PRL3-zumab for advanced age-related macular degeneration
This study tests a new injectable medicine called PRL3-zumab for patients with advanced wet macular degeneration (nAMD) whose condition hasn't improved enough with standard treatments. The goal is to see if this new approach can help preserve or improve vision in people who have already tried at least two other eye injections.
SingaporeAges 18 years+ - NCT07516132RecruitingPhase 3
Long-term safety study of axitinib implant for wet macular degeneration
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
Bakersfield, CaliforniaAges 50 years+ - NCT04985487Recruiting
Safety follow-up for brolucizumab in neovascular AMD
This study tracks the real-world safety of brolucizumab in adults with neovascular age-related macular degeneration (nAMD). If you’re already prescribed this medicine, the study may help confirm it continues to be safe and well-tolerated over time.
Daegu, Dalseo GuAges 18–100 - NCT07482176RecruitingPhase 3
Gene therapy trial for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (IXO-vec) for people with wet age-related macular degeneration (nAMD). It aims to reduce the need for frequent eye injections by helping the eye make its own medicine to block the growth of harmful blood vessels.
Mesa, ArizonaAges 50 years+ - NCT07367282RecruitingPhase 4
Faricimab for newly diagnosed wet age-related macular degeneration
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
SeongnamAges 50 years+ - NCT07317934RecruitingPhase 3
Gene therapy for wet age-related macular degeneration
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
Hefei, AnhuiAges 50–80 - NCT07308639Recruiting
Eye disease health data study in Germany
This study looks at health records in Germany to understand how many people have certain eye conditions like age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. It also tests new ways to use this information for research.
LeverkusenAges 18 years+ - NCT06031727RecruitingEarly Phase 1
CRISPR gene therapy for wet age-related macular degeneration
This trial tests a new CRISPR-based treatment for wet age-related macular degeneration (AMD). It aims to stop vision loss by targeting the cause of abnormal blood vessel growth in the eye. This study is for people who have already tried anti-VEGF injections but might not be responding well enough.
Shanghai, Shanghai MunicipalityAges 50–80 - NCT07275840RecruitingPhase 2
Testing IBI302 for wet age-related macular degeneration
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
Shanghai, Shanghai MunicipalityAges 50 years+ - NCT07249216Recruiting
Studying eye fluid to improve treatment for wet age-related macular degeneration
This study looks at whether certain proteins or molecules in the jelly-like fluid inside the eye can predict why some people with wet age-related macular degeneration do not respond well to standard anti-VEGF injections. By studying these signals, researchers hope to improve future treatment and better tailor care to individual patients.
SingaporeAges 50 years+ - NCT07064759RecruitingPhase 3
Gene therapy injection for wet age-related macular degeneration
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
Scottsdale, ArizonaAges 50 years+ - NCT07053358RecruitingEarly Phase 1
Gene therapy for wet AMD
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
ShanghaiAges 50 years+ - NCT07007065RecruitingPhase 3
Study of a gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
Mesa, ArizonaAges 50 years+ - NCT06847542RecruitingPhase 3
Study of a refillable eye implant for wet AMD
This trial tests a refillable eye implant (PDS) that slowly releases medication to treat wet age-related macular degeneration (nAMD). It aims to see if replacing the implant every 36 weeks works as well as regular eye injections.
InnsbruckAges 50 years+
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Neovascular Age-Related Macular Degeneration (nAMD) trials by city
Studies with a site in or near these metro areas.
Neovascular Age-Related Macular Degeneration (nAMD) trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for neovascular age-related macular degeneration (namd)?
- Yes. Clin2 currently lists 31 recruiting neovascular age-related macular degeneration (namd) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neovascular age-related macular degeneration (namd) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neovascular age-related macular degeneration (namd) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Neovascular Age-related Macular Degeneration
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-Related Macular Degeneration
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
- Wet Age-related Macular Degeneration (wAMD)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.